CFH and age-related macular degeneration: In our study, we investigated the TCC levels from the plasma of AMD patients and compared them with those from the plasma of AMD patients and age-matched controls as well as carriers of risk alleles CFH and ARMS2. Whereas AMD patients’ plasma showed higher TCC levels, there were no differences between plasma from AMD patients with either CFH or ARMS2 risk alleles.